161 related articles for article (PubMed ID: 15661225)
21. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
[TBL] [Abstract][Full Text] [Related]
22. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
23. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction.
Vasilevskaya IA; Rakitina TV; O'Dwyer PJ
Cancer Res; 2003 Jun; 63(12):3241-6. PubMed ID: 12810654
[TBL] [Abstract][Full Text] [Related]
24. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
25. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
[TBL] [Abstract][Full Text] [Related]
26. Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase.
Sun J; Liao JK
Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2238-44. PubMed ID: 15486309
[TBL] [Abstract][Full Text] [Related]
27. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
28. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
Rahmani M; Reese E; Dai Y; Bauer C; Kramer LB; Huang M; Jove R; Dent P; Grant S
Mol Pharmacol; 2005 Apr; 67(4):1166-76. PubMed ID: 15625278
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.
Münster PN; Srethapakdi M; Moasser MM; Rosen N
Cancer Res; 2001 Apr; 61(7):2945-52. PubMed ID: 11306472
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.
Sain N; Krishnan B; Ormerod MG; De Rienzo A; Liu WM; Kaye SB; Workman P; Jackman AL
Mol Cancer Ther; 2006 May; 5(5):1197-208. PubMed ID: 16731752
[TBL] [Abstract][Full Text] [Related]
31. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.
Castro JE; Prada CE; Loria O; Kamal A; Chen L; Burrows FJ; Kipps TJ
Blood; 2005 Oct; 106(7):2506-12. PubMed ID: 15972449
[TBL] [Abstract][Full Text] [Related]
32. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells.
Villa R; Folini M; Porta CD; Valentini A; Pennati M; Daidone MG; Zaffaroni N
Carcinogenesis; 2003 May; 24(5):851-9. PubMed ID: 12771028
[TBL] [Abstract][Full Text] [Related]
34. The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines.
Park JW; Yeh MW; Wong MG; Lobo M; Hyun WC; Duh QY; Clark OH
J Clin Endocrinol Metab; 2003 Jul; 88(7):3346-53. PubMed ID: 12843186
[TBL] [Abstract][Full Text] [Related]
35. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Schulte TW; Neckers LM
Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
[TBL] [Abstract][Full Text] [Related]
36. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
Burger AM; Fiebig HH; Stinson SF; Sausville EA
Anticancer Drugs; 2004 Apr; 15(4):377-87. PubMed ID: 15057143
[TBL] [Abstract][Full Text] [Related]
37. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
Terry J; Lubieniecka JM; Kwan W; Liu S; Nielsen TO
Clin Cancer Res; 2005 Aug; 11(15):5631-8. PubMed ID: 16061882
[TBL] [Abstract][Full Text] [Related]
38. Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin.
Yang J; Yang JM; Iannone M; Shih WJ; Lin Y; Hait WN
Cancer Res; 2001 May; 61(10):4010-6. PubMed ID: 11358819
[TBL] [Abstract][Full Text] [Related]
39. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
Münster PN; Basso A; Solit D; Norton L; Rosen N
Clin Cancer Res; 2001 Aug; 7(8):2228-36. PubMed ID: 11489796
[TBL] [Abstract][Full Text] [Related]
40. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
Kaur G; Belotti D; Burger AM; Fisher-Nielson K; Borsotti P; Riccardi E; Thillainathan J; Hollingshead M; Sausville EA; Giavazzi R
Clin Cancer Res; 2004 Jul; 10(14):4813-21. PubMed ID: 15269157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
